Mark N. Adams

2.6k total citations
65 papers, 1.5k citations indexed

About

Mark N. Adams is a scholar working on Molecular Biology, Oncology and Cancer Research. According to data from OpenAlex, Mark N. Adams has authored 65 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Molecular Biology, 30 papers in Oncology and 12 papers in Cancer Research. Recurrent topics in Mark N. Adams's work include DNA Repair Mechanisms (24 papers), Cancer-related Molecular Pathways (9 papers) and DNA and Nucleic Acid Chemistry (8 papers). Mark N. Adams is often cited by papers focused on DNA Repair Mechanisms (24 papers), Cancer-related Molecular Pathways (9 papers) and DNA and Nucleic Acid Chemistry (8 papers). Mark N. Adams collaborates with scholars based in Australia, United Kingdom and United States. Mark N. Adams's co-authors include Derek J. Richard, Kenneth J. O’Byrne, John D. Hooper, Emma Bolderson, David P. Fairlie, Jacky Y. Suen, Mei‐Kwan Yau, Rithwik Ramachandran, Morley D. Hollenberg and Nicolas Paquet and has published in prestigious journals such as Nucleic Acids Research, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Mark N. Adams

65 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Mark N. Adams Australia 21 908 385 307 271 204 65 1.5k
Siqing Shan United States 17 893 1.0× 347 0.9× 469 1.5× 129 0.5× 124 0.6× 25 1.7k
Harvey W. Smith Canada 13 836 0.9× 304 0.8× 450 1.5× 106 0.4× 131 0.6× 18 1.4k
Andrea Viale Italy 13 957 1.1× 361 0.9× 292 1.0× 224 0.8× 61 0.3× 19 1.3k
W. Clay Gustafson United States 19 1.6k 1.7× 487 1.3× 456 1.5× 144 0.5× 342 1.7× 38 2.3k
Yingmei Li China 20 816 0.9× 404 1.0× 407 1.3× 270 1.0× 248 1.2× 69 1.8k
Sonia Minuzzo Italy 21 824 0.9× 397 1.0× 325 1.1× 210 0.8× 64 0.3× 49 1.5k
Nianxiang Zhang United States 25 1.6k 1.8× 315 0.8× 328 1.1× 457 1.7× 84 0.4× 47 2.1k
Maurizio Di Liberto United States 17 1.1k 1.2× 494 1.3× 155 0.5× 225 0.8× 274 1.3× 49 1.8k
Alexander Thompson United Kingdom 25 1.3k 1.4× 196 0.5× 220 0.7× 389 1.4× 98 0.5× 68 1.9k
Dilara McCauley United States 18 1.3k 1.5× 456 1.2× 132 0.4× 350 1.3× 171 0.8× 56 1.7k

Countries citing papers authored by Mark N. Adams

Since Specialization
Citations

This map shows the geographic impact of Mark N. Adams's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark N. Adams with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark N. Adams more than expected).

Fields of papers citing papers by Mark N. Adams

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark N. Adams. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark N. Adams. The network helps show where Mark N. Adams may publish in the future.

Co-authorship network of co-authors of Mark N. Adams

This figure shows the co-authorship network connecting the top 25 collaborators of Mark N. Adams. A scholar is included among the top collaborators of Mark N. Adams based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark N. Adams. Mark N. Adams is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shah, Esha T., Christopher J. Molloy, Thomas Kryza, et al.. (2024). Inhibition of Aurora B kinase (AURKB) enhances the effectiveness of 5-fluorouracil chemotherapy against colorectal cancer cells. British Journal of Cancer. 130(7). 1196–1205. 8 indexed citations
2.
Shah, Esha T., et al.. (2023). An Exploration of Small Molecules That Bind Human Single-Stranded DNA Binding Protein 1. Biology. 12(11). 1405–1405. 3 indexed citations
3.
Fisher, Mark, Eric D. Boittier, Emma Bolderson, et al.. (2023). Structural investigation of CDCA3‐Cdh1 protein–protein interactions using in vitro studies and molecular dynamics simulation. Protein Science. 32(3). e4572–e4572. 1 indexed citations
4.
Monkman, James, Aaron T. Mayer, Ahmed M. Mehdi, et al.. (2023). Multi‐omic and spatial dissection of immunotherapy response groups in non‐small cell lung cancer. Immunology. 169(4). 487–502. 19 indexed citations
5.
Suraweera, Amila, Joshua T. Burgess, Chee Man Cheong, et al.. (2023). The fructose-bisphosphate, Aldolase A (ALDOA), facilitates DNA-PKcs and ATM kinase activity to regulate DNA double-strand break repair. Scientific Reports. 13(1). 15171–15171. 20 indexed citations
6.
Wiegmans, Adrian P., Pascal H. G. Duijf, Mark N. Adams, et al.. (2021). Genome instability and pressure on non-homologous end joining drives chemotherapy resistance via a DNA repair crisis switch in triple negative breast cancer. NAR Cancer. 3(2). zcab022–zcab022. 8 indexed citations
7.
Suraweera, Amila, Neha S. Gandhi, Joshua T. Burgess, et al.. (2021). COMMD4 functions with the histone H2A-H2B dimer for the timely repair of DNA double-strand breaks. Communications Biology. 4(1). 484–484. 11 indexed citations
8.
9.
Suraweera, Amila, Mark N. Adams, Pascal H. G. Duijf, et al.. (2021). Correction: Defining COMMD4 as an anti-cancer therapeutic target and prognostic factor in non-small cell lung cancer. British Journal of Cancer. 124(9). 1612–1612. 16 indexed citations
10.
Dave, Keyur A., Christopher J. Molloy, Neha S. Gandhi, et al.. (2021). Identification of Proteins Deregulated by Platinum-Based Chemotherapy as Novel Biomarkers and Therapeutic Targets in Non-Small Cell Lung Cancer. Frontiers in Oncology. 11. 615967–615967. 6 indexed citations
11.
Suraweera, Amila, Mark N. Adams, Pascal H. G. Duijf, et al.. (2020). Defining COMMD4 as an anti-cancer therapeutic target and prognostic factor in non-small cell lung cancer. British Journal of Cancer. 123(4). 591–603. 16 indexed citations
12.
Barr, Martin P., Susan Heavey, P. Godwin, et al.. (2019). Targeting NF-κB-mediated inflammatory pathways in cisplatin-resistant NSCLC. Lung Cancer. 135. 217–227. 26 indexed citations
13.
Adams, Mark N., Joshua T. Burgess, Yaowu He, et al.. (2017). Expression of CDCA3 Is a Prognostic Biomarker and Potential Therapeutic Target in Non–Small Cell Lung Cancer. Journal of Thoracic Oncology. 12(7). 1071–1084. 63 indexed citations
14.
Paquet, Nicolas, Mark N. Adams, Didier Boucher, et al.. (2016). Nucleophosmin: From structure and function to disease development. QUT ePrints (Queensland University of Technology). 3 indexed citations
15.
Burgess, Joshua T., Emma Bolderson, Mark N. Adams, et al.. (2016). Activation and cleavage of SASH1 by caspase-3 mediates an apoptotic response. QUT ePrints (Queensland University of Technology). 2 indexed citations
16.
O’Byrne, Kenneth J., Joshua T. Burgess, Emma Bolderson, et al.. (2016). 16P The overexpression of SASH1 stimulates cell death in lung cancer cells. Journal of Thoracic Oncology. 11(4). S62–S63. 3 indexed citations
17.
Paquet, Nicolas, Mark N. Adams, Didier Boucher, et al.. (2016). Nucleophosmin: from structure and function to disease development. BMC Molecular Biology. 17(1). 19–19. 188 indexed citations
18.
O’Byrne, Kenneth J., Mark N. Adams, Joshua T. Burgess, & Derek J. Richard. (2016). 24P CDCA3 regulates the cell cycle and modulates cisplatin sensitivity in non-small cell lung cancer. Journal of Thoracic Oncology. 11(4). S65–S65. 6 indexed citations
19.
Adams, Mark N., et al.. (2014). Triple primary cancers of the head and neck: case report and literature review. The Journal of Laryngology & Otology. 128(6). 552–554. 3 indexed citations
20.
Adams, Mark N., Charles N. Pagel, Eleanor J. Mackie, & John D. Hooper. (2012). Evaluation of antibodies directed against human protease-activated receptor-2. Naunyn-Schmiedeberg s Archives of Pharmacology. 385(9). 861–873. 20 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Siqing Shan Breakdown of academic impact, for papers by Harvey W. Smith Breakdown of academic impact, for papers by Andrea Viale Breakdown of academic impact, for papers by W. Clay Gustafson Breakdown of academic impact, for papers by Yingmei Li Breakdown of academic impact, for papers by Sonia Minuzzo Breakdown of academic impact, for papers by Nianxiang Zhang Breakdown of academic impact, for papers by Maurizio Di Liberto Breakdown of academic impact, for papers by Alexander Thompson Breakdown of academic impact, for papers by Dilara McCauley
Rankless by CCL
2026